Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 12, 2025
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 27, 2025
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 09, 2025
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Collaboration
AbbVie, Gedeon Richter Partner on Neuropsychiatric Drug Discovery
Details : Companies will discover and develop novel targets for the treatment of neuropsychiatric conditions. AbbVie will have worldwide commercialization rights except for traditional markets of Richter.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $25.0 million
October 24, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Sumitomo
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ryeqo (relugolix, estradiol, and norethisterone acetate) receives positive opinion by CHMP recommending approval in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
Product Name : Ryeqo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2023
Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Sumitomo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABBV-932
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Recipient : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 22, 2023
Lead Product(s) : ABBV-932
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Recipient : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ryeqo (relugolix, estradiol, and norethisterone acetate) receives approval from EU in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
Product Name : Ryeqo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2023
Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Collaboration
AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases
Details : The collaboration is based on results of preclinical research carried by Richter and includes several new chemical entities selected for development. AbbVie and Richter have collaborated for 15 years, including globally launched products such as caripraz...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 03, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : RGH-706
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 11, 2022
Lead Product(s) : RGH-706
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RGB-14-P
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 21, 2021
Lead Product(s) : RGB-14-P
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable